The trial, sponsored by the Asian Institute of Gastroenterology, investigates the impact of premedication timing on mucosal visibility during upper gastrointestinal endoscopy. Given the increasing prevalence of gastrointestinal disorders and the critical role of early detection in improving patient outcomes, this study addresses a significant clinical need. The findings could enhance procedural efficiency and diagnostic accuracy, potentially leading to broader adoption of simethicone and NAC in endoscopic practices. The market for gastrointestinal endoscopy is substantial, with ongoing advancements in imaging technologies. Successful outcomes may position the combination of simethicone and NAC as a standard premedication protocol, influencing competitive dynamics in the endoscopy market and attracting interest from pharmaceutical companies focused on gastrointestinal therapeutics.